🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • Limited research evidence available for ingredients
B Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Vegecap(s) Serving Size
100 Servings
Vitamin Product Type
0% Evidence Coverage

Supplement Facts — Evidence Check

MenaQ7
100 mcg

Other Ingredients

Microcrystalline Cellulose Hypromellose L-Leucine Silicon Dioxide

Label Claims — Verification

Nutrient
All Other
Structure/Function
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years) Gluten Free Dairy Free

Product Information

📋 Directions for Use

Directions: Adults: Take one (1) VegeCap daily with food as a dietary supplement or as recommended by your healthcare professional.

⚠️ Warnings & Precautions

Caution: Before using any dietary supplement, pregnant or lactating women should consult with a physician or health professional. If taking a blood-thinning medication, consult a healthcare practitioner before using.

Keep out of reach of children.

Do not use if safety seal is broken or missing.

To report a serious adverse event or to obtain product information contact 1-866-319-6299.

🧪 Formulation Notes

Free of: Egg, fish shellfish, wheat, peanuts, milk, soybeans and corn. Non-GMO, gluten free, soy free

Manufactured in a cGMP Compliant U.S.A. Facility

Vitamin K2 as Menaquinone 7 Clinically Proven MenaQ7 Vitamin K2 as MK-7

Additional Information

Keep bottle tightly closed. Store between 15 degrees-30 degrees C (59 degrees-86 degrees F).

cGMP

Product Details

UPC / SKU 8 19193 02116 3
DSLD Entry Date 2024-01-24
Product Type Vitamin
Form Capsule
DSLD ID 304860
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →